Literature DB >> 16155128

The antimalarial drug artemisinin alkylates heme in infected mice.

Anne Robert1, Françoise Benoit-Vical, Catherine Claparols, Bernard Meunier.   

Abstract

Heme alkylation by the antimalarial drug artemisinin is reported in vivo, within infected mice that have been treated at pharmacologically relevant doses. Adducts resulting from the alkylation of heme by the drug were characterized in the spleen of treated mice, and their glucuroconjugated derivatives were present in the urine. Because these heme-artemisinin adducts were not observed in noninfected mice, this report confirms that the alkylating activity of this antimalarial drug is related to the presence of the parasite in infected animals. The identification of heme-artemisinin adducts in mice should be considered as the signature of the alkylation capacity of artemisinin in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16155128      PMCID: PMC1224611          DOI: 10.1073/pnas.0500972102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

Review 1.  Medical need, scientific opportunity and the drive for antimalarial drugs.

Authors:  Robert G Ridley
Journal:  Nature       Date:  2002-02-07       Impact factor: 49.962

2.  Alkylation of human hemoglobin A0 by the antimalarial drug artemisinin.

Authors:  Katalin Selmeczi; Anne Robert; Catherine Claparols; Bernard Meunier
Journal:  FEBS Lett       Date:  2004-01-02       Impact factor: 4.124

Review 3.  A medicinal chemistry perspective on artemisinin and related endoperoxides.

Authors:  Paul M O'Neill; Gary H Posner
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

Review 4.  From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs.

Authors:  Anne Robert; Odile Dechy-Cabaret; Jérôme Cazelles; Bernard Meunier
Journal:  Acc Chem Res       Date:  2002-03       Impact factor: 22.384

Review 5.  Artemisinin: mechanisms of action, resistance and toxicity.

Authors:  Steven R Meshnick
Journal:  Int J Parasitol       Date:  2002-12-04       Impact factor: 3.981

Review 6.  Epidemiology of drug-resistant malaria.

Authors:  Chansuda Wongsrichanalai; Amy L Pickard; Walther H Wernsdorfer; Steven R Meshnick
Journal:  Lancet Infect Dis       Date:  2002-04       Impact factor: 25.071

Review 7.  Possible modes of action of the artemisinin-type compounds.

Authors:  P L Olliaro; R K Haynes; B Meunier; Y Yuthavong
Journal:  Trends Parasitol       Date:  2001-03

8.  Solution structures of antimalarial drug-heme complexes.

Authors:  Alison Leed; Kateri DuBay; Lyann M B Ursos; Devin Sears; Angel C De Dios; Paul D Roepe
Journal:  Biochemistry       Date:  2002-08-13       Impact factor: 3.162

9.  Artemisinins target the SERCA of Plasmodium falciparum.

Authors:  U Eckstein-Ludwig; R J Webb; I D A Van Goethem; J M East; A G Lee; M Kimura; P M O'Neill; P G Bray; S A Ward; S Krishna
Journal:  Nature       Date:  2003-08-21       Impact factor: 49.962

10.  Synthesis and antimalarial activity of trioxaquine derivatives.

Authors:  Odile Dechy-Cabaret; Françoise Benoit-Vical; Christophe Loup; Anne Robert; Heinz Gornitzka; Anne Bonhoure; Henri Vial; Jean-François Magnaval; Jean-Paul Séguéla; Bernard Meunier
Journal:  Chemistry       Date:  2004-04-02       Impact factor: 5.236

View more
  64 in total

1.  Structure-activity relationship of an ozonide carboxylic acid (OZ78) against Fasciola hepatica.

Authors:  Qingjie Zhao; Mireille Vargas; Yuxiang Dong; Lin Zhou; Xiaofang Wang; Kamaraj Sriraghavan; Jennifer Keiser; Jonathan L Vennerstrom
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

2.  The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials.

Authors:  Amy E Mercer; Ian M Copple; James L Maggs; Paul M O'Neill; B Kevin Park
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

3.  Trioxaquines and heme-artemisinin adducts inhibit the in vitro formation of hemozoin better than chloroquine.

Authors:  Christophe Loup; Joël Lelièvre; Françoise Benoit-Vical; Bernard Meunier
Journal:  Antimicrob Agents Chemother       Date:  2007-08-13       Impact factor: 5.191

4.  In vitro activities of trioxaquines against Schistosoma mansoni.

Authors:  Jérôme Boissier; Frédéric Coslédan; Anne Robert; Bernard Meunier
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

5.  Tafenoquine: A Step toward Malaria Elimination.

Authors:  Kuan-Yi Lu; Emily R Derbyshire
Journal:  Biochemistry       Date:  2020-02-24       Impact factor: 3.162

Review 6.  Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria.

Authors:  Richard T Eastman; David A Fidock
Journal:  Nat Rev Microbiol       Date:  2009-11-02       Impact factor: 60.633

7.  Pharmacokinetics of the Antischistosomal Lead Ozonide OZ418 in Uninfected Mice Determined by Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Anna Leonidova; Mireille Vargas; Jörg Huwyler; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

8.  Selection of a trioxaquine as an antimalarial drug candidate.

Authors:  Frédéric Coslédan; Laurent Fraisse; Alain Pellet; François Guillou; Benjamin Mordmüller; Peter G Kremsner; Alicia Moreno; Dominique Mazier; Jean-Pierre Maffrand; Bernard Meunier
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-05       Impact factor: 11.205

9.  Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.

Authors:  Erica M W Lauterwasser; Shaun D Fontaine; Hao Li; Jiri Gut; Kasiram Katneni; Susan A Charman; Philip J Rosenthal; Matthew Bogyo; Adam R Renslo
Journal:  ACS Med Chem Lett       Date:  2015-10-02       Impact factor: 4.345

10.  Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target.

Authors:  Shiming Zhang; Glenn S Gerhard
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.